Skip to main content

Table 3 Comparison of levels of auto-antibodies between the two groups

From: The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study

Auto-antibodiesCancer group (n = 51) (positive/total, percentage)Control group (n = 204) (positive/total, percentage)P value
ANA37/37, 100%198/200, 99.00%1.00
Anti-dsDNA15/35, 42.86%95/180, 52.78%0.36
Anti-Sm5/36, 13.89%33/172, 19.19%0.63
Anti-RO5226/37, 70.27%110/172, 63.95%0.57
Anti-RO6020/37, 54.05%110/172, 63.95%0.57
Anti-SSB4/36, 11.11%16/172, 9.30%0.76
Anti-Nuc11/36, 30.56%70/172, 40.70%0.35
Anti-His7/36, 19.44%50/172, 29.07%0.31
Anti-Rib10/36, 27.78%58/172, 33.72%0.56
Anti-nRNP11/36, 30.56%64/172, 37.21%0.57
  1. ANA antinuclear antibody, anti-dsDNA anti-double-stranded DNA antibody, anti-Sm anti-Sm antibody, anti-RO52 anti-RO52 antibody, anti-RO60 anti-RO60 antibody, anti-SSB anti-SSB antibody, anti-Nuc anti-nucleosome antibody, anti-His anti-histone antibody, anti-Rib anti-ribosome antibody, anti-nRNP anti-nRNP antibody